文献速递类风湿关节炎

重新审视排除患者整体评估的类风湿关节炎缓解标准:5792例患者个体荟萃分析

Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.
PubMed 文献 · Ann Rheum Dis · 2020-10-06

该个体患者数据荟萃分析纳入11项生物制剂随机对照试验的5792例类风湿关节炎患者,评估排除患者整体评估(PGA)后ACR/EULAR Boolean缓解标准对影像学和功能结局的预测价值。结果显示,排除PGA的3V缓解与原始4V缓解在预测影像学良好结局上效度相似,但功能良好结局预测较差,同时可能减少过度治疗。

要点

  • 4V近缓解预测影像学良好结局的概率(78%)与4V缓解(81%)无显著差异,但显著高于未缓解(72%)。
  • 采用3V缓解可使19%的参与者避免治疗升级,代价是额外6.1%、4.0%和0.7%的患者2年内ΔmTSS分别>0.0、>0.5和>5单位。
  • 4V近缓解的功能良好结局概率(67%)显著低于4V缓解(78%),与未缓解(69%)相似。

核心结论

  • 排除PGA的3V缓解与原始4V缓解在预测影像学良好结局上效度相似,但功能良好结局预测较差,可能减少过度治疗风险。

研究设计与样本

  • 基于11项生物制剂随机对照试验的个体患者数据荟萃分析,共纳入5792例类风湿关节炎患者,评估≥2年的影像学和功能结局。

主要发现

  • 4V缓解组占23%,4V近缓解组占19%;4V近缓解的影像学良好结局概率为78%,数值低于4V缓解的81%但无统计学显著性,显著高于未缓解的72%(差异=6%,95%CI 2%至10%)。
  • 4V近缓解的功能良好结局概率为67%(95%CI 63%至71%),显著低于4V缓解的78%(74%至81%),与未缓解的69%(66%至72%)相似。
  • 采用3V缓解可使19%的参与者避免治疗升级,代价是额外6.1%、4.0%和0.7%的患者2年内ΔmTSS分别>0.0、>0.5和>5单位。

关键数值与推荐

  • 4V缓解定义为TJC28/SJC28、CRP(mg/dL)和PGA(0-10,最差)均≤1;4V近缓解为除PGA>1外其余相同;3V缓解为不含PGA的TJC28/SJC28和CRP均≤1;未缓解为TJC28>1和/或SJC28>1和/或CRP>1。
  • 影像学良好结局定义为第二年ΔmTSS≤0.5单位,功能良好结局定义为第二年HAQ-DI变化≤0.0。

临床怎么用

  • 3V缓解可作为免疫抑制治疗目标的探索方向,并辅以以患者为导向的目标,以平衡影像学保护和减少过度治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of excluding patient global assessment (PGA) from the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission criteria, on prediction of radiographic and functional outcome of rheumatoid arthritis (RA). METHODS: Meta-analyses using individual patient data from randomised controlled trials testing the efficacy of biological agents on radiographic and functional outcomes at ≥2 years. Remission states were defined by 4 variants of the ACR/EULAR Boolean definition: (i) tender and swollen 28-joint counts (TJC28/SJC28), C reactive protein (CRP, mg/dL) and PGA (0-10=worst) all ≤1 (4V-remission); (ii) the same, except PGA >1 (4V-near-remission); (iii) 3V-remission (i and ii combined; similar to 4V, but without PGA); (iv) non-remission (TJC28 >1 and/or SJC28 >1 and/or CRP >1). The most stringent class achieved at 6 or 12 months was considered. Good radiographic (GRO) and functional outcome (GFO) were defined as no worsening (ie, change in modified total Sharp score (ΔmTSS) ≤0.5 units and ≤0.0 Health Assessment Questionnaire-Disability Index points, respectively, during the second year). The pooled probabilities of GRO and GFO for the different definitions of remission were estimated and compared. RESULTS: Individual patient data (n=5792) from 11 trials were analysed. 4V-remission was achieved by 23% of patients and 4V-near-remission by 19%. The probability of GRO in the 4V-near-remission group was numerically, but non-significantly, lower than that in the 4V-remission (78 vs 81%) and significantly higher than that for non-remission (72%; difference=6%, 95% CI 2% to 10%). Applying 3V-remission could have prevented therapy escalation in 19% of all participants, at the cost of an additional 6.1%, 4.0% and 0.7% of patients having ΔmTSS >0.0, >0.5 and >5 units over 2 years, respectively. The probability of GFO (assessed in 8 trials) in 4V-near-remission (67%, 95% CI 63% to 71%) was significantly lower than in 4V-remission (78%, 74% to 81%) and similar to non-remission (69%, 66% to 72%). CONCLUSION: 4V-near-remission and 3V-remission have similar validity as the original 4V-remission definition in predicting GRO, despite expected worse prediction of GFO, while potentially reducing the risk of overtreatment. This supports further exploration of 3V-remission as the target for immunosuppressive therapy complemented by patient-oriented targets.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ferreira RJO, Welsing PMJ, Jacobs JWG, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Ann Rheum Dis. 2020. PMID: 33023964. doi:10.1136/annrheumdis-2020-217171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。